Related Experiment Video
Updated: Oct 5, 2025

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration
Published on: May 19, 2016
TLK1-mediated MK5-S354 phosphorylation drives prostate cancer cell motility and may signify distinct pathologies
Md Imtiaz Khalil1, Vibha Singh1, Judy King2
1Department of Biochemistry and Molecular Biology, LSU Health Sciences Center, Shreveport, LA, USA.
Abstract:
Metastases account for the majority of prostate cancer (PCa) deaths, and targeting them is a major goal of systemic therapy. We identified a novel interaction between two kinases: tousled-like kinase 1 (TLK1) and MAP kinase-activated protein kinase 5 (MK5) that promotes PCa spread. In PCa progression, TLK1-MK5 signalling appears to increase following antiandrogen treatment and in metastatic castration-resistant prostate cancer (mCRPC) patients. Determinations of motility rates (2D and 3D) of different TLK1- and MK5-perturbed cells, including knockout (KO) and knockdown (KD), as well as the use of specific inhibitors, showed the importance of these two proteins for in vitro dissemination. We established that TLK1 phosphorylates MK5 on three residues (S160, S354 and S386), resulting in MK5 activation, and additionally, mobility shifts of MK5 also supported its phosphorylation by TLK1 in transfected HEK 293 cells. Expression of MK5-S354A or kinase-dead MK5 in MK5-depleted mouse embryonic fibroblast (MEF) cells failed to restore their motility compared with that of wild-type (WT) MK5-rescued MK5-/- MEF cells. A pMK5-S354 antiserum was used to establish this site as an authentic TLK1 target in androgen-sensitive human prostate adenocarcinoma (LNCaP) cells, and was used in immunohistochemistry (IHC) studies of age-related PCa sections from TRAMP (transgenic adenocarcinoma of the mouse prostate) mice and to probe a human tissue microarray (TMA), which revealed pMK5-S354 level is correlated with disease progression (Gleason score and nodal metastases). In addition, The Cancer Genome Atlas (TCGA) analyses of PCa expression and genome-wide association study (GWAS) relations identify TLK1 and MK5 as potential drivers of advanced PCa and as markers of mCRPC. Our work suggests that TLK1-MK5 signalling is functionally involved in driving PCa cell motility and clinical features of aggressiveness; hence, disruption of this axis may inhibit the metastatic spread of PCa.
Insights
A novel TLK1-MK5 signaling pathway drives prostate cancer (PCa) spread and aggressiveness. Targeting this interaction may inhibit metastatic castration-resistant prostate cancer (mCRPC) progression.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Prostate cancer (PCa) metastases are the primary cause of mortality.
- Targeting metastatic disease is a critical goal for systemic therapies.
- The role of specific kinase interactions in PCa progression remains incompletely understood.
Purpose of the Study:
- To identify and characterize novel molecular mechanisms driving PCa metastasis.
- To investigate the functional interaction between tousled-like kinase 1 (TLK1) and MAP kinase-activated protein kinase 5 (MK5) in PCa.
- To evaluate the potential of the TLK1-MK5 axis as a therapeutic target for advanced PCa.
Main Methods:
- Cellular assays measuring motility (2D and 3D) in TLK1- and MK5-perturbed cells (knockout/knockdown) and with specific inhibitors.
- Biochemical analyses to determine TLK1-mediated phosphorylation of MK5 at specific residues (S160, S354, S386).
- Immunohistochemistry (IHC) on mouse and human PCa tissues, and analysis of The Cancer Genome Atlas (TCGA) data.
Main Results:
- TLK1 directly phosphorylates and activates MK5, promoting PCa cell motility and in vitro dissemination.
- Elevated TLK1-MK5 signaling is observed in advanced PCa, including metastatic castration-resistant prostate cancer (mCRPC) and correlates with Gleason score and nodal metastasis.
- TCGA and GWAS analyses suggest TLK1 and MK5 are potential drivers and markers of advanced PCa.
Conclusions:
- The TLK1-MK5 signaling axis is a key driver of prostate cancer cell motility and aggressive clinical features.
- This pathway is upregulated during PCa progression, particularly in response to antiandrogen treatment and in mCRPC.
- Disruption of the TLK1-MK5 interaction represents a promising therapeutic strategy to inhibit PCa metastasis.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Destabilization of Microtubules

